Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives

Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system, characterized by an extremely aggressive clinical phenotype. Patients with GBM have a poor prognosis and only 3–5% of them survive for more than 5 years. The current GBM treatment standards include maximal resection...

Descripción completa

Detalles Bibliográficos
Autores principales: Szopa, Wojciech, Burley, Thomas A., Kramer-Marek, Gabriela, Kaspera, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337853/
https://www.ncbi.nlm.nih.gov/pubmed/28316990
http://dx.doi.org/10.1155/2017/8013575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337853/
https://www.ncbi.nlm.nih.gov/pubmed/28316990
http://dx.doi.org/10.1155/2017/8013575

Ejemplares similares